Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 43, 2012, Pages 17561-17566

  Huang, Yuhui ^a   Yuan, Jianping ^a   Righi, Elda ^a   Kamoun, Walid S ^a   Ancukiewicz, Marek ^a   Nezivar, Jean ^a   Santosuosso, Michael ^a   Martin, John D ^a   Martin, Margaret R ^a   Vianello, Fabrizio ^a   Leblanc, Pierre ^a   Munn, Lance L ^a   Huang, Peigen ^a   Duda, Dan G ^a   Fukumura, Dai ^a   Jain, Rakesh K ^a   Poznansky, Mark C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Hypoxia; Myeloid derived suppressor cell; Tumor tissue vaccine; Vascular normalization

Indexed keywords

CANCER VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; MITOMYCIN C; MONOCLONAL ANTIBODY DC101; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOTHERAPY; MICE; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84867902940     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1215397109     Document Type: Article

References (38)

1. Madan RA, Gulley JL, Fojo T, Dahut WL (2010) Therapeutic cancer vaccines in prostate cancer: The paradox of improved survival without changes in time to progression. Oncologist 15:969-975.
2. Rosenberg SA, et al. (2005) Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 175:6169-6176. (Pubitemid 41508105)
3. Offringa R (2006) Cancer. Cancer immunotherapy is more than a numbers game. Science 314:68-69.
4. Jain RK (2005) Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307:58-62.
5. Schmid MC, Varner JA (2010) Myeloid cells in the tumor microenvironment: Modulation of tumor angiogenesis and tumor inflammation. J Oncol 2010:201026.
6. DeNardo DG, et al. (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1(1):54-67.
7. Quezada SA, Peggs KS, Simpson TR, Allison JP (2011) Shifting the equilibrium in cancer immunoediting: From tumor tolerance to eradication. Immunol Rev 241:104-118.
8. Schlom J (2012) Therapeutic cancer vaccines: Current status and moving forward. J Natl Cancer Inst 104:599-613.
9. Hamzah J, et al. (2008) Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453:410-414. (Pubitemid 351693122)
10. Huang Y, et al. (2007) Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 110:624-631. (Pubitemid 47105401)
11. Wu NZ, Klitzman B, Dodge R, Dewhirst MW (1992) Diminished leukocyte-endothelium interaction in tumor microvessels. Cancer Res 52:4265-4268.
12. Jochems C, Schlom J (2011) Tumor-infiltrating immune cells and prognosis: The potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood) 236:567-579.
13. Liyanage UK, et al. (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756-2761. (Pubitemid 34921025)
14. Biswas SK, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat Immunol 11:889-896.
15. Schmid MC, et al. (2011) Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression. Cancer Cell 19:715-727.
16. Corzo CA, et al. (2010) HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 207:2439-2453.
17. Rolny C, et al. (2011) HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19:31-44.
18. Huang Y, Snuderl M, Jain RK (2011) Polarization of tumor-associated macrophages: A novel strategy for vascular normalization and antitumor immunity. Cancer Cell 19:1-2.
19. Winkler F, et al. (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553-563. (Pubitemid 40017699)
20. Chauhan VP, et al. (2012) Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 7:383-388.
21. Sorensen AG, et al. (2012) Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 72:402-407.
22. Li B, et al. (2006) Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res 12:6808-6816. (Pubitemid 44876851)
23. Manning EA, et al. (2007) A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res 13:3951-3959. (Pubitemid 47037603)
24. Shrimali RK, et al. (2010) Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 70:6171-6180.
25. Righi E, et al. (2011) CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res 71:5522-5534.
26. Prewett M, et al. (1999) Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59:5209-5218. (Pubitemid 29503984)
27. Olive PL, Chaplin DJ, Durand RE (1985) Pharmacokinetics, binding and distribution of Hoechst 33342 in spheroids and murine tumours. Br J Cancer 52:739-746. (Pubitemid 16238124)
28. Lin EY, et al. (2003) Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 163:2113-2126. (Pubitemid 37310040)
29. Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298-307.
30. Hurwitz H, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342. (Pubitemid 38702844)
31. Sandler A, et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550. (Pubitemid 44917502)
32. Miller K, et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676.
33. Robert NJ, et al. (2011) RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252-1260.
34. Miles DW, et al. (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3239-3247.
35. Van Cutsem E, Lambrechts D, Prenen H, Jain RK, Carmeliet P (2011) Lessons from the adjuvant bevacizumab trial on colon cancer: What next? J Clin Oncol 29:1-4.
36. Johansson A, Hamzah J, Payne CJ, Ganss R (2012) Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy. Proc Natl Acad Sci USA 109:7841-7846.
37. Farsaci B, Higgins JP, Hodge JW (2012) Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer 130:1948-1959.
38. Huang P, Duda DG, Jain RK, Fukumura D (2008) Histopathologic findings and establishment of novel tumor lines from spontaneous tumors in FVB/N mice. Comp Med 58:253-263. (Pubitemid 351954731)